Home > Insider Trading > Filing (0001104659-20-032715)

Filing Details

Accession Number:: 0001104659-20-032715
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2020-03-12 21:39:06
Reporting Period:: 2020-03-10

Accepted Time:: 2020-03-12 21:39:06
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1175151	Cytosorbents Corp	CTSO	Surgical & Medical Instruments & Apparatus (3841)	980373793

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1368151	Vincent Capponi	C/O Cytosorbents Corporation 7 Deer Park Drive, Suite K Monmouth Junction NJ 08852	Chief Operating Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2020-03-10	6,500	$3.45	417,649	No	4	M	Direct
Common Stock	Acquisiton	2020-03-10	4,677	$3.45	422,326	No	4	M	Direct
Common Stock	Disposition	2020-03-10	4,677	$6.00	417,649	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (right to buy)	Disposition	2020-03-10	6,500	$0.00	6,500	$3.45
Common Stock	Stock Option (right to buy)	Disposition	2020-03-10	4,677	$0.00	4,677	$3.45

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
14,800		2020-05-05	No	4	M	Direct
10,123		2020-05-05	No	4	M	Direct

Footnotes

Stock option exercise conducted pursuant to a 10b5-1 trading plan adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended (the "Exchange Act").
Open market sale conducted pursuant to a 10b5-1 trading plan adopted by the reporting person in accordance with Rule 10b5-1 of the Exchange Act.
Includes: (i) the following RSUs that will be settled into common stock upon vesting upon a "Change In Control" of CytoSorbents Corporation (the "Company") as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan: (a) 17,900 RSUs granted on February 24, 2017, (b) 54,000 RSUs granted on June 7, 2016, (c) 125,000 RSUs granted on April 8, 2015 and (d) 10,100 RSUs granted on March 15, 2018; and (ii) the following RSUs (which vest as to one-third of the award on each of the date of grant, the first anniversary of the date of grant, and the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date) and will settle into common stock, par value $0.001 per share (the "Common Stock") of the Company upon vesting: (a) 36,067 RSUs granted on February 28, 2020 and unvested on the date hereof; (b) 36,067 RSUs granted on July 22, 2019 and unvested on the date hereof; (continued in footnote 4)
(continued from footnote 3) and (c) 1,540 RSUs granted on March 4, 2019 and unvested on the date hereof; and (iii) 136,975 shares of common stock owned by the reporting person.
These stock options were originally granted on May 5, 2010 and vested at the discretion of the Company's Board of Directors based on satisfying certain criteria including a timely completion of the sepsis trial, raising capital for the Company, and partnering and business development.